CVS Health Corp. (NYSE:CVS) on Wednesday posted upbeat first-quarter earnings and issued strong 2026 guidance.
The health solutions company reported adjusted earnings of $2.57 per share, surpassing analyst estimates of $2.20. Sales reached $100.43 billion, up 6.2% year over year, beating the consensus of $95.09 billion.
CVS Health raised fiscal 2026 adjusted earnings guidance from $7.00-$7.20 per share to $7.30-$7.50, compared to the consensus of $7.16. The company expects 2026 sales of more than $405 billion, compared to prior guidance of at least $400 million and the Wall Street estimate of $404.87 billion.
“CVS Health continues to provide what people want most from health care: a connected, convenient, cost-effective engagement experience across our unique collection of businesses. We build trust every day in communities across the country by providing better access, affordability and care to nearly 185 million people. Our positive performance is driven by strong execution across our enterprise. We will continue to build momentum through delivering on our strategy and a steadfast focus on our purpose – to simplify health care one person, one family and one community at a time.”
CVS Health shares fell 0.1% to trade at $86.74 on Thursday.
These analysts made changes to their price targets on CVS Health following earnings announcement.
- Evercore ISI Group analyst Elizabeth Anderson maintained the stock with an Outperform rating and raised the price target from $100 to $105.
- Truist Securities analyst David Macdonald maintained the stock with a Buy and raised the price target from $98 to $102.
- Barclays analyst Andrew Mok maintained the stock with an Overweight rating and boosted the price target from $93 to $101.
- RBC Capital analyst Ben Hendrix maintained CVS Health with an Outperform rating and raised the price target from $93 to $107.
Considering buying CVS stock? Here’s what analysts think:
Photo via Shutterstock
Recent Comments